bevacizumab,cetuximab
roche,eli lilly
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'cetuximab', ' bev ', 'fire-4', 'bevacizumab']
folfoxiri plus cetuximab or bevacizumab as 1st line treatment of mbrafv600e #coloncancer how to treat braf mutant crc answer provided by phs-ii fire-4.5 trial when you use a triplet, bev should be the biologic agent of choice 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology